Splendid article on The Effects Of Stem Cell Therapy In The Treatment Of Childhood Acute Lymphoblastic Leukemia published in Journal of Stem Cell Research. Researchers believe that stem cell therapies may offer alternative options to high-risk patients.
Acute Lymphoblastic Leukemia (ALL) is a cancerous transformation in the blood and bone marrow beginning with progenitor cells. With developing research into treatment options, there is now a 90% survival rate. However, high relapse rates have become the next challenge to overcome.
Acute Lymphoblastic Leukemia is a cancer of the blood and bone marrow caused by the inability of progenitor cells to replicate properly. A high-risk factor indicative of ALL is the occurrence of chromosomal translocations and replications. While ALL survival rates have reached 90%, relapse rates remain high. Survival depends on a number of factors including the age of diagnosis, white blood cell count, and response to chemotherapy. While studies have supported the use of HSC’s in the treatment of ALL, there is more research to be done in the hopes of reducing both secondary malignancies and relapse.